The UK regulatory agency has approved Bafna for the manufacturing of Finasteride in strength of 5 mg.
Finasteride is an antiandrogen which acts by inhibiting 5-alpha reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT). It works by blocking the body’s production of the male hormone that causes the prostate to enlarge.
Bafna Pharmaceuticals CMD Mahaveer Chand Bafna said that Bafna Pharma has been constantly upgrading its manufacturing facilities to efficiently meet the anticipated demands of the global markets.
"The approval from UK MHRA for Finasteride 5 mg will enable Bafna Pharma to widen the customer base in Europe," Chand Bafna said.